Compare · EW vs LFWD
EW vs LFWD
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Lifeward Ltd. (LFWD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and LFWD operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.25B, about 2286.1x LFWD ($22.0M).
- Over the past year, EW is up 16.7% and LFWD is down 12.0% - EW leads by 28.7 points.
- EW has been more active in the news (7 items in the past 4 weeks vs 4 for LFWD).
- EW has more recent analyst coverage (25 ratings vs 1 for LFWD).
- Company
- Edwards Lifesciences Corporation
- Lifeward Ltd.
- Price
- $88.84+1.83%
- $7.78-2.51%
- Market cap
- $50.25B
- $22.0M
- 1M return
- +3.03%
- +11.39%
- 1Y return
- +16.70%
- -11.98%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2014
- News (4w)
- 7
- 4
- Recent ratings
- 25
- 1
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
Latest LFWD
- SEC Form D filed by Lifeward Ltd.
- Lifeward Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Lifeward Secures Growth Capital to Accelerate Commercial Expansion with Up to $11.2 Million in Strategic Financing
- Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
- SEC Form SD filed by Lifeward Ltd.
- SEC Form S-8 filed by Lifeward Ltd.
- SEC Form 10-Q filed by Lifeward Ltd.
- Chief Medical Officer Rose Keith Dale was granted 15,000 units of Ordinary Shares, increasing direct ownership by 720% to 17,083 units (SEC Form 4)
- New insider Rose Keith Dale claimed ownership of 2,083 units of Ordinary Shares (SEC Form 3)
- Lifeward Ltd. filed SEC Form 8-K: Other Events